Targeting and Reconstructing Cancer Signalings Using CRISPR-Cas Effectors: Promoting Cancer Diagnostics and Therapeutics

Submission Deadline: 30 November 2022 (closed) Submit to Special Issue

Guest Editors

Dr. Yonghao Zhan,
Zhengzhou University, Zhengzhou, China
yonghao_zhan@163.com

Dr. Yujing Li,
Indiana University, Purdue University Indianapolis
Indianapolis, United States
liben@iu.edu

Dr. Yuchen Liu,
Shenzhen Second People's Hospital, Shenzhen, China
liuyuchenmdcg@163.com

Summary

The bacterial type II clustered regularly interspaced short palindromic repeat (CRISPR)–CRISPR-associated nuclease 9 (Cas9) system provides a modular tool for genome editing and regulation. Since the programmability of the CRISPR system was first reported, it has been widely used in various genetic engineering studies. Synthetic circuits based on CRISPR-Cas effectors can determine the benign and malignant states of cells and specifically activate apoptotic genes to kill cancer cells by sensing the overall expression pattern of a group of cancer-promoting and tumor-suppressing factors. 

The aim of the current Research Topic is to develop novel cancer diagnostic and therapeutic tools based on reprogrammed CRISPR-Cas technologies. Areas to be covered in this Research Topic may include, but are not limited to: The use of the CRISPR system to target cancer gene expression; CRISPR-mediated regulation of cancer signaling pathways; Construction of internal cancer suicide systems using CRISPR effectors; Cancer gene therapy based on CRISPR technology. 


Keywords

CRISPR Technology, Cancer, Gene Circuits, Gene Therapy, Synthetic Biology

Share Link

WeChat scan